[1]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77-90.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(01):77-90.
点击复制

黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
27
期数:
2014年01期
页码:
77-90
栏目:
出版日期:
2014-01-14

文章信息/Info

Title:
Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy
文章编号:
1004-6852(2014)01-0077-14
作者:
任芳1，2，徐厚谦1△
1 甘肃中医学院，甘肃 兰州 730000； 2 金昌市第一人民医院内科
Author(s):
REN Fang1,2, XU Houqian1△
1 Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China; 2 Department of Internal Medicine in Jinchang Municipal the First People′s Hospital
关键词:
糖尿病肾病; 黄芪注射液; 随机对照试验; 系统评价; Meta分析
Keywords:
diabetic nephropathy;  HuangQi injection;  randomized controlled trial;  systematic review;  Meta analysis
分类号:
R587.1
文献标志码:
A
摘要:
目的：系统评价黄芪注射液治疗糖尿病肾病的有效性及安全性。方法：计算机检索Cochrane图书馆临床对照试验库、MEDLINE、EMBASE、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方数据库，同时手工检索相关会议论文、学位论文及所获文献的参考文献，收集黄芪注射液治疗糖尿病肾病的随机或半随机对照试验。由2名研究者独立筛选和提取资料，并按照改良Jadad评分量表对纳入文献质量进行评价，应用Rev Man 4.2.2软件进行Meta分析。结果：共纳入16个RCT，1058例DN患者。大部分试验方法学质量较低且样本含量小。“漏斗图”呈不对称分布，提示可能存在发表偏倚（提示阴性结果的试验可能未发表）及试验方法质量低下。Meta分析结果显示：①与空白对照组相比，黄芪注射液可降低DN患者24小时尿蛋白、血尿素氮、甘油三酯，并且可改善DN患者症状和体征的总有效率；②与空白对照组相比，黄芪注射液可降低早期DN患者24小时尿白蛋白排泄率、24小时尿蛋白、血清肌酐、血尿素氮、甘油三酯、总胆固醇，但不能降低临床期和晚期DN患者的血清肌酐和总胆固醇；③黄芪注射液降低早期DN患者的24小时尿白蛋白排泄率、血清肌酐、血尿素氮的疗效与卡托普利相似；降低早期DN患者24小时尿白蛋白排泄率、血尿素氮的疗效与奥扎格雷钠注射液相似，但降低早期DN患者血清肌酐的疗效不如奥扎格雷钠注射液。治疗期间尚未发现严重不良反应。结论：黄芪注射液可能是一种相对安全和有效治疗早期糖尿病肾病的药物。由于纳入试验方法质量低下和可能存在的发表偏倚，使本系统评价的证据强度不足，有待进一步进行高质量的大样本、随机双盲对照试验来证实。
Abstract:
Objective: To assess the effectiveness and safety of HuangQi injection in treating diabetic nephropathy(DN) systematically. Methods: The papers about randomized or semi-randomized controlled trials (RCT) of HuangQi injection in treating DN were collected and searched in Cochrane library clinical controlled trials database, MEDLINE, EMBASE, CNKI, CBM, WangFang database, as well as related conference papers, dissertations and the reference in the obtained literature. Two investigators chose the trials and drew the informations indenpedently, the quality of the included studies was evaluated with modified Jadad rating scale, Meta analysis was performed with software Rev Man 4.2.2. Results: Altogether 16 RCTs were included and there were 1058 patients. Most of trial methodologies were of lower quality and with small sample size.“Funnel plots” were not equally distributed, which suggested that publication bias might be existed (it showed that trial with negative results might not be published) and the qualities of trial methodologies were lower. The results of Meta analysis showed:①compared with blank control group, HuangQi injection could reduce 24 hours urinary protein, blood urea nitrogen(BUN) and glycerin trilaurate(TG) of DN patients, and improve total effective rates of body signs and symptom of DN patients;②compared with blank control group,HuangQi injection could decrease 24 hours urine albumin excretion rate (UAER), 24 hours urinary protein, serum creatinine(Scr), BUN, TG and total cholesterol(TC) of DN patients at early stage,but it couldn’t lower Scr and TC of DN patients at clinical stage and advanced stage; ③ HuangQi injection presented similar effects to captopril in decreasing 24 hours UAER, Scr and BUN of DN patients at early stage; it also was similar to sodium ozagrel injection in lowering 24 hours UAER and BUN of DN patients at early stage, but it showed less effects in decreasing Scr of DN patients at early stage as sodium ozagrel injection. There was no severe adverse reaction during the treatment. Conclusion: HuangQi injection might be a kind of drug which is relatively safe and effective in treating early DN. Due to low methodological quality of included trial and the might existing publication bias, the evidence is not strong enough, therefore, randomized double-blind controlled trials of high quality large sample are needed to be proved further.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):62.
[3]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(01):96.
[4]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[5]王晓怀,寇嘉宁,潘文,等.黄芪注射液治疗脑梗死的Meta分析[J].西部中医药,2014,27(10):67.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]杨国军.黄芪注射液对2型糖尿病患者血管功能及微循环状态的影响[J].西部中医药,2015,28(05):109.
[8]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):68.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):96.
[11]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):1.

备注/Memo

备注/Memo:
收稿日期：2013-06-17作者简介：任芳(1982—)，女，硕士学位，主治医师。研究方向：内分泌疾病的中西医结合治疗。△通讯作者：徐厚谦(1960—)，男，硕士研究生导师，教授。研究方向：高校教学和心血管疾病的中医药防治。
更新日期/Last Update: 2014-01-15